Does an all-condition case management program for high-risk patients reduce health care utilization in medicaid and medicare beneficiaries with diabetes?

2019 ◽  
Vol 33 (6) ◽  
pp. 445-450
Author(s):  
Linh Phuong Bui ◽  
Felicia Hill-Briggs ◽  
Nola Durkin ◽  
Ariella Apfel ◽  
Patti L. Ephraim ◽  
...  
2021 ◽  
Author(s):  
Maureen Smith ◽  
Menggang Yu ◽  
Jared Huling ◽  
Xinyi Wang ◽  
Allie DeLonay ◽  
...  

BACKGROUND Impactability modeling promises to help solve the nationwide crisis in caring for high-need high-cost patients by matching specific case management programs with patients using a “benefit” or “impactability” score, but there are limitations in tailoring each model to a specific program and population. OBJECTIVE We evaluated the impact on Medicare ACO savings from developing a benefit score for patients enrolled in an historic case management program, then prospectively implementing the score and evaluating the results in a new case management program. METHODS We conducted a longitudinal cohort study of 76,140 patients in a Medicare ACO with multiple before-and-after measures of the outcome using linked electronic health records and Medicare claims data from 2012 to 2019. There were 489 patients in the historic case management program and 1,550 matched comparison patients; 830 patients in the new program with 2,368 matched comparisons. The historic program targeted high-risk patients and assigned a centrally-located registered nurse and social worker to each patient. The new program targets high- and moderate-risk patients and assigns a nurse physically located in a primary care clinic. Our primary outcomes were any unplanned hospital events (admissions, observation stays, and ED visits), count of event-days, and Medicare payments. RESULTS In the historic program, as expected, high-benefit patients enrolled in case management had fewer events, fewer event-days, and an average $1.15 million reduction in Medicare payments per 100 patients over the subsequent year when compared to matched comparisons. For the new program, high-benefit high-risk patients enrolled in case management had fewer events, while high-benefit moderate-risk patients enrolled in case management did not differ from matched comparisons. CONCLUSIONS Although there was evidence that a benefit score could be extended to a new case management program for similar (i.e., high-risk) patients, there was no evidence that it could be extended to a moderate-risk population. Extending a score to a new program and population should include evaluation of program outcomes within key subgroups. With the increased attention to value-based care, policy makers and measure developers should consider ways to incorporate impactability modeling into program design and evaluation. CLINICALTRIAL N/A


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Bhanu Prasad ◽  
Maryam Jafari ◽  
Lexis Gordon ◽  
Navdeep Tangri ◽  
Joanne Kappel

Abstract Background and Aims: Multidisciplinary clinics (MDC’s) were established in Canada to offer a variety of support systems (diabetes care, social support, easy access to pharmacists, dietitians, specialty trained nurses), to monitor and delay progression through timed lab investigations and visits in conjunction with the Nephrologist. The reasons for better outcomes have been identified as better education, focus on self-care, dietary interventions, timely transplant referrals, modality education, lower hospitalizations and mortality. Treating all patients with chronic kidney disease (CKD) as part of a multidisciplinary care team runs the risk of adding unwarranted labs, interventions, polypharmacy and costs. Kidney Failure Risk Equation (KFRE) uses routine laboratory and clinical data, to stratify patients into three risk categories (low, medium, and high risk) of progression. KFRE has been shown to accurately estimate progression to kidney failure in adults with CKD. The objectives of the study were to i) validate the KFRE in our CKD patients, ii) evaluate health care utilization of patients based on the risk of progression in our province, Saskatchewan. iii) identify the subgroup of patients that benefit most from follow up in MDC. Methods: We conducted a retrospective study on 1007 patients with CKD stages G3 and G4 in two CKD multidisciplinary clinics in the province of Saskatchewan, Canada (January 2004-December 2012). The predicted risk of kidney failure (low, medium high) for each patient was calculated using the 8-variable KFRE. Patients were followed for five years to validate the KFRE; data on initiation of dialysis or death was collected. Cost of delivery of care per patient per year in the CKD clinic was determined. Health care utilization was evaluated by measuring the number/cost of hospital admissions, cardiovascular and thoracic (CVT) surgery, non-nephrology specialist appointments, and medications. Results: There were more patients in G 3 (n= 533) than in G 4 (n=474). 313 (59%), 150 (28%), and 70 (13%) were in low, medium and high-risk categories for G 3 CKD. 275 (58%), 86 (18%), and 113 (24%) were in similar categories for G 4. The mean age (SD) was 71 (12.8) years. The number of patients > 65 years of age was 75%. 57% were men, mean GFR (mls/min/1.73m2) for G3 was 40 (7.8) and 23 (4) for G4. Of the G3 patients, 4% of low risk, 11% of the medium risk and 26% of the high risk progressed to dialysis by 5 years. In G 4 patients, 7% of low risk, 17% of medium risk and 48% of high risk progressed to dialysis over 2 years. These results validate the KFRE in our population. The cost of care per patient in MDC was $ 3800 (CAD) per year. There was a difference in the cost of medications, number and cost of (inpatient hospitalizations, cardiovascular surgeries, non-Nephrology specialist visits, and day surgeries) between low risk patients vs high risk patients in G4 patients. Conclusion: We performed a cost-effectiveness analysis of our MDC’s and show that very few patients at low-risk of progression advance to ESRD. They are also unlikely to benefit from intensive care management and better managed in primary care with advice from tertiary centres. Individual programs have significant opportunity to improve health care delivery by identifying the sub- groups that benefit the most from MDC based on the risk of progression to allow optimal utilization of resources. At $ 3800 (CAD) per patient, we suggest that MDC’s are best utilized by patients with medium and high risk of progression. Further, we show that patients that the low-risk patients were older, had fewer inpatient visits, had lesser drug costs, underwent fewer cardiovascular surgeries, had fewer day surgery visits, and fewer non-nephrology specialist visits. This is the first study to our knowledge that focuses on health care utilization based on the risk of disease progression rather than the stage of CKD.


2015 ◽  
Vol 11 (3) ◽  
pp. 241-246 ◽  
Author(s):  
John Abisheganaden ◽  
Yew Ding ◽  
Wai Chong ◽  
Bee Heng ◽  
Akash Verma ◽  
...  

2019 ◽  
Vol 179 (2) ◽  
pp. 161 ◽  
Author(s):  
Lee A. Jennings ◽  
Alison M. Laffan ◽  
Anna C. Schlissel ◽  
Erin Colligan ◽  
Zaldy Tan ◽  
...  

2010 ◽  
Vol 13 (3) ◽  
pp. A7
Author(s):  
FX Liu ◽  
GC Alexander ◽  
SY Crawford ◽  
AS Pickard ◽  
DR Hedeker ◽  
...  

Medicine ◽  
2019 ◽  
Vol 98 (12) ◽  
pp. e14871 ◽  
Author(s):  
Kiran Raj Pandey ◽  
Fan Yang ◽  
Kathleen A. Cagney ◽  
Fabrice Smieliauskas ◽  
David O. Meltzer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document